Information  X 
Enter a valid email address

Witan Inv Tst PLC (WTAN)

  Print      Mail a friend       Annual reports

Wednesday 15 May, 2019

Witan Inv Tst PLC

Transaction in Own Shares

RNS Number : 1743Z
Witan Investment Trust PLC
15 May 2019
 

WITAN INVESTMENT TRUST PLC

 

15 May 2019

 

Market Purchase by the Company of its own Ordinary Shares

Witan Investment Trust plc hereby gives notification that, pursuant to the authority granted at the Annual General Meeting of the Company held on 1 May 2019 to make market purchases of the Company's own shares, a market purchase of 8,571 ordinary shares of 25p each of the Company was made today at a price of 1049.90 pence per share.  These shares will be held in treasury.

Following the purchase of the above share, the number of ordinary shares of 25p each held by the Company in treasury is 23,333,093 and the total number of ordinary shares of 25p each that the Company has in issue, including shares held in treasury, is 200,071,000.

In line with the Company's published policy any re-sale of treasury shares will only take place at a premium to the prevailing net asset value per share at the time of issue and therefore the shares held in treasury do not give rise to a potential dilution to net asset value per share.

The capital of the Company with full voting rights is now 176,737,907 ordinary shares of 25p each.  On a poll, ordinary shareholders have one vote for every £1 in nominal value (i.e. four ordinary shares are required for one vote).  Therefore, the total number of voting rights is 44,184,476 (i.e. one vote for every four shares in issue) and this figure may be used as the denominator for calculations of interests in the Company's voting rights.

 

-ENDS-

 

 

For further information please contact:

 

Andrew Bell

Chief Executive Officer

Witan Investment Trust plc

Tel: 020 7227 9770

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
POSCKPDBABKDDPD

a d v e r t i s e m e n t